• Profile
Close

Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: A randomized clinical trial

JAMA Jun 05, 2021

Furuta S, Nakagomi D, Kobayashi Y, et al. - Via performing this randomized clinical trial, researchers sought to compare efficacy and adverse events linked with a reduced-dose glucocorticoid plus rituximab regimen vs the standard high-dose glucocorticoid plus rituximab regimen in remission induction of ANCA-associated vasculitis. A total of 140 patients with newly diagnosed ANCA-associated vasculitis were included. In the reduced-dose glucocorticoid plus rituximab group, there were 71.0% patients with disease remission at 6 months relative to 69.2% in the high-dose glucocorticoid plus rituximab group, a difference that met the prespecified noninferiority margin of −20 percentage points. These findings suggest noninferiority of reduced-dose glucocorticoid plus rituximab regimen to a high-dose glucocorticoid plus rituximab regimen with regard to induction of disease remission.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay